Download PDF
Thromb Haemost 1992; 67(01): 095-100
DOI: 10.1055/s-0038-1648387
Original Articles
Schattauer GmbH Stuttgart

An Enzyme-Linked Immunosorbent Assay for Urokinase-Type Plasminogen Activator (u-PA) and Mutants and Chimeras Containing the Serine Protease Domain of u-PA

Paul J Declerck
The Center for Thrombosis and Vascular Research, University of Leuven, Leuven, Belgium
,
Leen Van Keer
The Center for Thrombosis and Vascular Research, University of Leuven, Leuven, Belgium
,
Maria Verstreken
The Center for Thrombosis and Vascular Research, University of Leuven, Leuven, Belgium
,
Désiré Collen
The Center for Thrombosis and Vascular Research, University of Leuven, Leuven, Belgium
› Author Affiliations
Further Information

Publication History

Received 20 March 1991

Accepted after revision 11 July 1991

Publication Date:
02 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

An enzyme-linked immunosorbent assay (ELISA) for quantitation of natural and recombinant plasminogen activators containing the serine protease domain (B-chain) of urokinase-type plasminogen activator (u-PA) was developed, based on two murine monoclonal antibodies, MA-4D1E8 and MA-2L3, raised against u-PA and reacting with non-overlapping epitopes in the B-chain. MA-4D1E8 was coated on microtiter plates and bound antigen was quantitated with MA-2L3 conjugated with horseradish peroxidase. The intra-assay, inter-assay and inter-dilution coefficients of variation of the assay were 6%, 15% and 9%, respectively. Using recombinant single-chain u-PA (rscu-PA) as a standard, the u-PA-related antigen level in normal human plasma was 1.4 ± 0.6 ng/ml (mean ± SD, n = 27).

The ELISA recognized the following compounds with comparable sensitivity: intact scu-PA (amino acids, AA, 1 to 411), scu-PA-32k (AA 144 to 411), a truncated (thrombin-derived) scu-PA comprising A A 157 to 411, and chimeric t-PA/u-PA molecules including t-PA(AA1-263)/scu-PA(AA144-411), t-PA(AA1-274)/scu-PA(AA138-411) and t-PA(AA87-274)/scu-PA(AA138-411). Conversion of single-chain to two-chain forms of u-PA or inhibition of active two-chain forms with plasminogen activator inhibitor-1 or with the active site serine inhibitor phenyl-methyl-sulfonyl fluoride, did not alter the reactivity in the assay. In contrast, inactivation with α2-antiplasmin or with the active site histidine inhibitor Glu-Gly-Arg-CH2Cl resulted in a 3- to 5-fold reduction of the reactivity. When purified scu-PA-32k was added to pooled normal human plasma at final concentrations ranging from 20 to 1,000 ng/ml, recoveries in the ELISA were between 84 and 110%.

The assay was successfully applied for the quantitation of pharmacological levels of scu-PA and t-PA(AA87_274)/scu-PA(AA138-411) in plasma during experimental thrombolysis in baboons.

Thus the present ELISA, which is specifically dependent on the presence of the serine protease part of u-PA, is useful for measurement of a wide variety of variants and chimeras of u-PA which are presently being developed for improved thrombolytic therapy.

 

  • References

  • 1 Collen D. On the regulation and control of fibrinolysis. Thromb Haemostas 1980; 43: 77-89
    PubMedGoogle Scholar
  • 2 Collen D. Molecular mechanisms of fibrinolysis and their application to fibrin-specific thrombolytic therapy. J Cell Biochem 1987; 33: 77-86
    CrossrefPubMedGoogle Scholar
  • 3 Reich E. Activation of plasminogen: a general mechanism for producing localized extracellular proteolysis. In: Molecular Basis of Biological Degradation Processes. Berlin RD. et al (eds). Academic Press; New York: 1978. pp 155-169
    Google Scholar
  • 4 Dano K, Andreasen PA, Grondahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 1985; 44: 139-266
    PubMedGoogle Scholar
  • 5 Blasi F, Vassalli JD, Dano K. Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors. J Cell Biol 1987; 104: 801-804
    CrossrefPubMedGoogle Scholar
  • 6 Van de Werf F, Nobuhara M, Collen D. Coronary thrombolysis with human single-chain urokinase-type plasminogen activator (prourokinase) in patients with acute myocardial infarction. Ann Intern Med 1986; 104: 345-348
    CrossrefPubMedGoogle Scholar
  • 7 Lijnen HR, Van Hoef B, De Cock F, Collen D. The mechanism of plasminogen activation and fibrin dissolution by single-chain urokinase-type plasminogen activator in a plasma milieu in vitro. Blood 1989; 73: 1864-1872
    PubMedGoogle Scholar
  • 8 Declerck PJ, Lijnen HR, Verstreken M, Moreau H, Collen D. A monoclonal antibody specific for two-chain urokinase-type plasminogen activator. Application to the study of the mechanism of clot lysis with single-chain urokinase-type plasminogen activator in plasma. Blood 1990; 75: 1794-1800
    PubMedGoogle Scholar
  • 9 Holmes WE, Pennica D, Blaber M, Rey MW, Giinzler WA, Steffens GJ, Heyneker HL. Cloning and expression of the gene for prourokinase in Escherichia coli . Biotechnology 1985; 3: 923-929
    CrossrefPubMedGoogle Scholar
  • 10 Barlow GH, Francis CW, Marder VJ. On the conversion of high molecular weight urokinase to the low molecular weight form by plasmin. Thromb Res 1981; 23: 541-547
    CrossrefPubMedGoogle Scholar
  • 11 Stump DC, Lijnen HR, Collen D. Purification and characterization of a novel low molecular weight form of single-chain urokinase-type plasminogen activator. J Biol Chem 1986; 261: 17120-17126
    PubMedGoogle Scholar
  • 12 Darras V, Thienpont M, Stump DC, Collen D. Measurement of urokinase-type plasminogen activator (u-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies. Thromb Haemostas 1986; 56: 411-414
    PubMedGoogle Scholar
  • 13 Binnema DJ, van Iersel JJL, Dooijewaard G. Quantitation of urokinase antigen in plasma and culture media by use of an ELISA. Thromb Res 1986; 43: 569-577
    CrossrefPubMedGoogle Scholar
  • 14 Nielsen LS, Grondahl-Hansen J, Andreasen PA, Skriver L, Zeuthen J, Dano K. Enzyme-linked immunosorbent assay for human urokinase-type plasminogen activator and its proenzyme using a combination of monoclonal and polyclonal antibodies. J Immunoassay 1986; 7: 209-228
    PubMedGoogle Scholar
  • 15 Nakamura M, Ogawa H, Tsunematsu T. Characterization of a monoclonal antibody against human urokinase: development of a competitive ELISA for urokinase antigen. Acta Haematol Jpn 1987; 50: 158-167
    PubMedGoogle Scholar
  • 16 Grondahl-Hansen J, Agerlin N, Munkholm-Larsen P, Bach F, Nielsen LS, Dombernowsky P, Dano K. Sensitive and specific enzyme-linked immunosorbent assay for urokinase-type plasminogen activator and its application to plasma from patients with breast cancer. J Lab Clin Med 1988; 111: 42-51
    PubMedGoogle Scholar
  • 17 Mahmoud-Alexandroni M, Heath AB, Gaffney PJ. Sensitive and direct assays for functionally active plasminogen activators (tissue-type and urokinase-type) in plasma. Am J Clin Pathol 1989; 92: 308-314
    CrossrefPubMedGoogle Scholar
  • 18 Wojta J, Binder BR, Huber K, Hoover RL. Evaluation of fibrinolytic capacity in plasma during thrombolytic therapy with single (scu-PA) or two-chain urokinase-type plasminogen activator (tcu-PA) by a combined assay system for urokinase type plasminogen activator antigen and function. Thromb Haemostas 1989; 61: 289-293
    PubMedGoogle Scholar
  • 19 Nelles L, Lijnen HR, Collen D, Holmes WE. Characterization of a fusion protein consisting of amino acids 1 to 263 of tissue-type plasminogen activator and amino acids 144 to 411 of urokinase-type plasminogen activator. J Biol Chem 1987; 262: 10855-10862
    PubMedGoogle Scholar
  • 20 Lijnen HR, Nelles L, Van Hoef B, Demarsin E, Collen D. Characterization of a chimeric plasminogen activator consisting of amino acids 1 to 274 of tissue-type plasminogen activator and amino acids 138 to 411 of single-chain urokinase-type plasminogen activator. J Biol Chem 1988; 263: 19083-19091
    PubMedGoogle Scholar
  • 21 Nelles L, Lijnen HR, Van Nuffelen A, Demarsin E, Collen D. Characterization of domain deletions and/or duplication mutants of a recombinant chimera of tissue-type plasminogen activator and urokinase-type plasminogen activator (rt-PA/u-PA). Thromb Haemostas 1990; 64: 53-60
    PubMedGoogle Scholar
  • 22 Collen D, Lu HR, Lijnen HR, Nelles L, Stassen JM. Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators. Circulation 1991; 84: 1216-1234
    CrossrefPubMedGoogle Scholar
  • 23 Dewerchin M, Lijnen HR, Van Hoef B, De Cock F, Collen D. Biochemical properties of conjugates of urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin. Eur J Biochem 1989; 185: 141-149
    CrossrefPubMedGoogle Scholar
  • 24 Collen D, Stassen JM, Demarsin E, Kieckens L, Lijnen HR, Nelles L. Pharmacokinetics and thrombolytic properties of chimaeric plasminogen activators consisting of the NH2-terminal region of human tissue-type plasminogen activator and the COOH-terminal region of human single chain urokinase-type plasminogen activator. J Vase Med Biol 1989; 1: 234-240
    PubMedGoogle Scholar
  • 25 Bode C, Matsueda GR, Hui KY, Haber E. Antibody-directed urokinase: a specific fibrinolytic agent. Science 1985; 229: 765-767
    CrossrefPubMedGoogle Scholar
  • 26 Haber E, Quertermous T, Matsueda GR, Runge MS. Innovative approaches to plasminogen activator therapy. Science 1989; 243: 51-56
    CrossrefPubMedGoogle Scholar
  • 27 Bode C, Runge MS, Schonermark S, Eberle T, Newel JB, Kubler W, Haber E. Conjugation to antifibrin Fab’ enhances fibrinolytic potency of single-chain urokinase plasminogen activator. Circulation 1990; 81: 1974-1980
    CrossrefPubMedGoogle Scholar
  • 28 Pannekoek H, Lijnen HR, Loskutoff DJ. Recommendations for the nomenclature of mutant fibrinolytic genes and their proteins. Report of SSC Fibrinolysis Subcommittee 1990. Thromb Haemostas 1990; 64: 600-603
    PubMedGoogle Scholar
  • 29 Pennica D, Holmes WE, Kohr WJ, Harkins RN, Vehar GA, Ward CA, Bennet WF, Yelverton E, Seeburg PH, Heyneker HL, Goeddel DV, Collen D. Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli . Nature 1983; 301: 214-221
    CrossrefPubMedGoogle Scholar
  • 30 Lijnen HR, Nelles L, Holmes WE, Collen D. Biochemical and thrombolytic properties of a low molecular weight form (comprising Leu144 through Leu411) of recombinant single-chain urokinase-type plasminogen activator. J Biol Chem 1988; 263: 5594-5598
    PubMedGoogle Scholar
  • 31 Wiman B. Affinity chromatographic purification of human alpha2-antiplasmin. Biochem J 1980; 191: 229-232
    CrossrefPubMedGoogle Scholar
  • 32 Alessi MC, Declerck PJ, De Mol M, Nelles L, Collen D. Purification and characterization of natural and recombinant human plasminogen activator inhibitor 1 (PAI-1). Eur J Biochem 1988; 175: 531-540
    CrossrefPubMedGoogle Scholar
  • 33 Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Anal Biochem 1976; 72: 248-254
    CrossrefPubMedGoogle Scholar
  • 34 Lijnen HR, Uytterhoeven M, Collen D. Inhibition of trypsin-like serine proteinases by tripeptide arginyl and lysyl chloromethyl-ketones. Thromb Res 1984; 34: 431-437
    CrossrefPubMedGoogle Scholar
  • 35 Lijnen HR, Van Hoef B, Collen D. Comparative kinetic analysis of the activation of human plasminogen by natural and recombinant single-chain urokinase-type plasminogen activator. Biochim Biophys Acta 1986; 884: 402-408
    CrossrefPubMedGoogle Scholar
  • 36 Galfre G, Milstein C. Preparation of monoclonal antibodies: strategies and procedures. Methods Enzymol 1981; 73: 3-46
    PubMedGoogle Scholar
  • 37 Fazekas de St Groth S, Scheidegger D. Production of monoclonal antibodies: strategies and tactics. J Immunol Methods 1980; 35: 1-21
    CrossrefPubMedGoogle Scholar
  • 38 Anderson PN, Potter M. Induction of plasma cell tumors in Balb/c mice with 2, 6, 10, 14 tetramethyl-pentadecane (pristane). Nature 1969; 222: 994-995
    CrossrefPubMedGoogle Scholar
  • 39 Ey PL, Prowse SJ, Jenkin CR. Isolation of pure IgGi, IgG2a and IgG2b immunoglobulins from mouse serum using protein A-Sepharose. Immunochemistry 1978; 15: 429-436
    CrossrefPubMedGoogle Scholar
  • 40 Nakane PK, Kawaoi A. Peroxidase labeled antibody. A new method for conjugation. J Histochem Cytochem 1974; 22: 1084-1091
    CrossrefPubMedGoogle Scholar
  • 41 Holvoet P, Cleemput H, Collen D. Assay of human tissue-type plasminogen activator (t-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies to t-PA. Thromb Haemostas 1985; 54: 684-687
    PubMedGoogle Scholar
  • 42 Kirchheimer JC, Huber K, Polterauer P, Binder BR. Urokinase antigen in plasma of patients with liver cirrhosis and hepatoma. Thromb Haemostas 1985; 54: 617-618
    PubMedGoogle Scholar